Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials

por Ziemssen, F., Feltgen, N., Holz, FG., Guthoff, R., Ringwald, A., Bertelmann, T., Wiedon, A., Korb, C.
Publicado 2017

A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related...

por Holz, F. G., Schmitz-Valckenberg, Steffen, Wolf, A., Agostini, H., Lorenz, K., Pielen, A., Feltgen, N., Guthoff, R., Quiering, C., Clemens, A., Jaeger, K.
Publicado 2022